Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Ohio Accuses UnitedHealth’s OptumRx of Drug Overcharges

Nate Raymond  |  March 23, 2019

(Reuters)—Ohio’s attorney general on Monday said he had filed a lawsuit against UnitedHealth Group Inc’s OptumRx unit, saying the pharmacy benefit manager had overcharged the state nearly $16 million for prescription drugs.

Ohio Attorney General Dave Yost’s lawsuit followed a probe into the extent pharmacy benefit managers (PBMs) like OptumRx had engaged in pricing practices that resulted in the state overpaying for drugs for people covered by state health programs.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The probe, begun under Gov. Mike DeWine before he left his position of attorney general earlier this year, came amid public concerns about skyrocketing drug prices and the role that PBMs as pharmacy middlemen play in contributing to the costs.

Attorney General Yost accused OptumRx of failing for nearly three years to provide agreed-upon discounts for generic drugs purchased by injured workers submitting claims to the Ohio Bureau of Workers’ Compensation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Our review of PBM practices throughout state government is still ongoing,” Attorney General Yost said in a statement. “These are the first raindrops, but there’s a storm a-comin’.”

The lawsuit, filed on Friday in Franklin County Court of Common Pleas, seeks at least $15 million in compensatory damages and $15 million in punitive damages.

OptumRx did not immediately respond to a request for comment. It has previously said the state’s overcharging claims are “without merit.”

PBMs negotiate drug prices for employers and health plans. They typically demand steep discounts off the drugmakers’ list prices for medicines in exchange for including their products on the PBMs’ preferred formularies, or lists of drugs approved for reimbursement.

In Ohio, the Bureau of Workers’ Compensation and the state’s Medicaid program contract with PBMs to manage drug prescriptions for the agencies’ clients.

Yost, who was elected attorney general in November, previously served as the state’s auditor.

In that role, he released a report in August that found PBMs had charged the state’s Medicaid program an average “spread” of 31 percent for generic drugs, billing $208 million more from April 2017 through March 2018 than it cost to reimburse pharmacies.

OptumRx is the PBM for one of Ohio’s five Medicaid managed-care plans. CVS Health’s CVS Caremark unit acts as the PBM for the other four. The two companies administer $2.5 billion in annual Medicaid drug spending for Ohio.

OptumRx had also contracted with the workers’ compensation agency. But last year, the agency announced it had hired another company to manage its pharmaceutical program for injured workers amid claims OptumRx overcharged it.

Page: 1 2 | Single Page
Share: 

Filed under:Legal UpdatesProfessional Topics Tagged with:lawsuitLegalOhiopharmacy benefit managerspharmacy benefit managers (PBMs)

Related Articles

    Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

    August 8, 2022

    As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.

    High Cost of Specialty Drugs Demands Action

    July 6, 2021

    Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

    Arkansas PBM Bill: A Step in the Right Direction

    April 4, 2018

    During a three-day special legislative session in March, Arkansas Governor Asa Hutchinson (R) signed into law the first bill in the U.S. intended to address a lack of transparency among pharmacy benefit managers (PBMs) and their role in the high cost of prescription drugs.1 The bill, H.B. 1010: Arkansas Pharmacy Benefits Manager Licensure Act, will…

    Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting

    January 19, 2018

    SAN DIEGO—Pharmacy benefit managers (PBMs) and their impact on drug prices and access to high-cost medications by the patients rheumatologists treat was a major theme at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. In one session, industry experts tried to clarify the role for prior authorizations and drug formulary policies and explored ways to constructively…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences